AIMS: This study aimed to examine the feasibility of utilizing dynamic contrast-enhanced MRI (DCE-MRI) of the breast for the planning of surgical intervention following neoadjuvant therapy for locally advanced breast cancer (LABC). METHODS: Following their neoadjuvant therapy, women with LABC were followed-up by DCE-MRI in addition to clinical examination and mammography. If any modality suggested residual disease, surgery was carried out--initially salvage mastectomy and then breast-conserving surgery where appropriate. RESULTS: Seventeen women were recruited: stage III (n=16), stage IV (n=1) mean age 55 (range 34-74). Following neoadjuvant therapy, 10 mastectomies and two local excisions were performed for 10 histologically confirmed residual cancers. Median follow-up for those women not undergoing surgery is 3.24 (IQR 2.8-3.5) years. DCE-MRI proved 100% accurate for the delineation of residual disease and facilitated the planning of the local excisions. Clinical examination and mammography proved inaccurate (PPV 83% and 75% and NPV 55% and 80%, respectively). CONCLUSIONS: DCE-MRI is a potentially accurate method of delineating residual tumour following neoadjuvant therapy for LABC and may be used to plan appropriate operative intervention where required. Copyright 2001 Harcourt Publishers Limited.
AIMS: This study aimed to examine the feasibility of utilizing dynamic contrast-enhanced MRI (DCE-MRI) of the breast for the planning of surgical intervention following neoadjuvant therapy for locally advanced breast cancer (LABC). METHODS: Following their neoadjuvant therapy, women with LABC were followed-up by DCE-MRI in addition to clinical examination and mammography. If any modality suggested residual disease, surgery was carried out--initially salvage mastectomy and then breast-conserving surgery where appropriate. RESULTS: Seventeen women were recruited: stage III (n=16), stage IV (n=1) mean age 55 (range 34-74). Following neoadjuvant therapy, 10 mastectomies and two local excisions were performed for 10 histologically confirmed residual cancers. Median follow-up for those women not undergoing surgery is 3.24 (IQR 2.8-3.5) years. DCE-MRI proved 100% accurate for the delineation of residual disease and facilitated the planning of the local excisions. Clinical examination and mammography proved inaccurate (PPV 83% and 75% and NPV 55% and 80%, respectively). CONCLUSIONS:DCE-MRI is a potentially accurate method of delineating residual tumour following neoadjuvant therapy for LABC and may be used to plan appropriate operative intervention where required. Copyright 2001 Harcourt Publishers Limited.
Authors: Hakmook Kang; Allison Hainline; Lori R Arlinghaus; Stephanie Elderidge; Xia Li; Vandana G Abramson; Anuradha Bapsi Chakravarthy; Richard G Abramson; Brian Bingham; Kareem Fakhoury; Thomas E Yankeelov Journal: J Med Imaging (Bellingham) Date: 2017-12-29
Authors: Atin Saha; Kyung K Peck; Eric Lis; Andrei I Holodny; Yoshiya Yamada; Sasan Karimi Journal: Spine (Phila Pa 1976) Date: 2014-11-15 Impact factor: 3.468
Authors: Xia Li; Hakmook Kang; Lori R Arlinghaus; Richard G Abramson; A Bapsi Chakravarthy; Vandana G Abramson; Jaime Farley; Melinda Sanders; Thomas E Yankeelov Journal: Transl Oncol Date: 2014-02-01 Impact factor: 4.243
Authors: Jacob U Fluckiger; Mary E Loveless; Stephanie L Barnes; Martin Lepage; Thomas E Yankeelov Journal: Phys Med Biol Date: 2013-03-04 Impact factor: 3.609
Authors: Richard G Abramson; Lori R Arlinghaus; Jared A Weis; Xia Li; Adrienne N Dula; Eduard Y Chekmenev; Seth A Smith; Michael I Miga; Vandana G Abramson; Thomas E Yankeelov Journal: Breast Cancer (Dove Med Press) Date: 2012-10